Recently, Panni et al. demonstrated in a murine pancreatic cancer model that a partial agonist of CD11b+ repolarized TAMs and reduced MDSC infiltration while enhancing intratumoral CD103+ DC populations, rendering previously resistant murine pancreatic tumors responsive to checkpoint blockade (141). This evidence concerns the gene ITGAM and pancreatic neoplasm.